Established the principle of “synthetic essentiality” and identified CHD1 as a synthetic-essential gene in PTEN-deficient cancers. This study identified a novel PTEN pathway in cancer and provided a framework for the discovery of ‘trackable’ targets in cancers that harbor specific tumor-suppressor deficiencies.